An open-label trial to assess the safety of regorafenib in Turkish patients with metastatic colorectal cancer (mCRC) that progressed on standard therapy (REGARD)


Dane F., Ozgurdal K., Yalcin S., Benekli M., Aykan N. F. , Yucel I., ...Daha Fazla

ESMO 17th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 1 - 04 Temmuz 2015, cilt.26 identifier